Raptiva

Active Ingredient(s): Efalizumab
FDA Approved: * October 27, 2003
Pharm Company: * GENENTECH
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Raptiva Overview

Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -mab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a[1] subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out...

Read more Raptiva Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Efalizumab

Recent Raptiva Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Efalizumab
  • Powder for Reconstitution: 125mg
  • Vial: 125mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Efalizumab or a similar ingredient: (1 result)